← ANALYST RATINGS · TIPRANKS
CytomX Therapeutics (CTMX): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $13.25, the highest $16.00, the lowest $11.00. The average is +481.1% from the last price of $2.28.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $2.50+25.0% | Hold | +9.6% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $2.00−20.0% | Hold | −12.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $2.00−20.0% | Hold | −12.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 → $2.00−20.0% | Hold | −12.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 → $2.00−20.0% | Sell | −12.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $2.00−20.0% | Sell | −12.3% | Downgrade | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 → $2.00−20.0% | Hold | −12.3% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $12.00 | Buy | +426.3% | Reiterated | 13.10.26on TipRanks 09:25 | −3.9%next day −3.0% | ↗ |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 | Sell | +9.6% | Downgrade | 05.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $2.50−16.7% | Hold | +9.6% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | +9.6% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $2.50−16.7% | Hold | +9.6% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 → $3.00+20.0% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 → $3.00+20.0% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 → $3.00+20.0% | Hold | +31.6% | Reiterated | 01.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.50 | Hold | +9.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.50 | Hold | +9.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.50 | Hold | +9.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.50 | Sell | +9.6% | Downgrade | 29.09.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.50 | Hold | +9.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.50 | Hold | +9.6% | Reiterated | 29.09.26on TipRanks 00:05 | — | |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $12.00 | Buy | +426.3% | Reiterated | 23.09.26on TipRanks 08:15 | −4.7%next day −1.0% · 5 days −1.5% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $11.00 | Buy | +382.5% | Reiterated | 17.08.26on TipRanks 08:07 | +3.2%next day −1.1% · 5 days −3.4% | ↗ |
| Michael Schmidt★★★★★★★★★★#126 · hits 58% · avg +31.7% | Guggenheim | $15.00 → $14.00−6.7% | Buy | +514.0% | Reiterated | 07.08.26on TipRanks Aug 10 07:35 | +2.1%next day −0.5% · 5 days −3.3% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $16.00 | Buy | +601.8% | Reiterated | 07.08.26on TipRanks 04:19 | +2.1%next day −0.5% · 5 days −3.3% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $11.00 | Buy | +382.5% | Reiterated | 04.06.26on TipRanks 08:10 | −1.6%next day −3.1% · 5 days −3.7% | ↗ |
| Kalpit Patel★★★★★★★★★★#1436 · hits 39% · avg +16.1% | Wolfe Research | $6.00 | Buy | +163.2% | Initiated | 19.05.26on TipRanks 06:15 | +4.7%next day +1.2% · 5 days +2.4% | ↗ |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $17.00 → $11.00−35.3% | Buy | +382.5% | Reiterated | 11.05.26on TipRanks 21:20 | +0.7%next day −2.9% · 5 days −5.6% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $10.00 → $12.00+20.0% | Buy | +426.3% | Reiterated | 20.03.26on TipRanks Mar 23 07:50 | −5.5%next day −0.8% · 5 days +3.8% | ↗ |
| Roger Song★★★★★★★★★★#4779 · hits 41% · avg +2.6% | Jefferies | $8.00 → $16.00+100.0% | Buy | +601.8% | Reiterated | 18.03.26on TipRanks 10:30 | −17.9%next day +8.9% · 5 days −3.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering CytomX Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $13.25 at a price of $2.72 (+387.1%); now: $13.00 at $2.28 (+470.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 7 | 7 | 6 | 6 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.07 (from $-0.11 to $0.03). Last quarter: $-0.09.
Sales
Next quarter’s sales estimate — $10M (from $2M to $37M). Last quarter: $1M.
Best top-analyst consensus in the sector · Healthcare
About CytomX Therapeutics
- CEO: Sean A. McCarthy
- Employees: 69
- 151 Oyster Point Boulevard, South San Francisco, CA, 94080, US
- www.cytomx.com
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
Data from the stock’s TipRanks forecast page, read 24 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗